BioSpace

ESMO 2026: Amgen’s Imdelltra slashes death risk by nearly 60% in small cell lung cancer

When used alongside AstraZeneca’s Imfinzi, the bispecific T cell engager Imdelltra extended survival by eight months versus Imfinzi alone in Phase 3 study testing the combo in a first-line maintenance setting—a potentially “practice-changing” outcome, according to Truist Securities.

By BioSpace

1 min read
ESMO 2026: Amgen’s Imdelltra slashes death risk by nearly 60% in small cell lung cancer
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights